Linked Life Data

7691117

Source:http://linkedlifedata.com/resource/pubmed/id/7691117

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1993-11-23
pubmed:abstractText
The present phase I study was designed to determine the maximum tolerated dose (MTD) of epirubicin, administered every 3 weeks to patients with advanced non-small cell lung cancer (NSCLC), and combined with a conventional dose of vinorelbine [25 mg/m2 intravenously (i.v.) days 1 and 8] with or without the support of granulocyte-colony stimulating factor (G-CSF). 18 patients entered the study. The patients received the following four dose levels of epirubicin (i.v., day 1): 50 mg/m2 (3 patients) and 60 mg/m2 (6 patients) without G-CSF, 75 mg/m2 (3 patients) and 90 mg/m2 (6 patients) with G-CSF (5 micrograms/kg days 4-6 and 9-15). In the patients treated without G-CSF the MTD of epirubicin was 60 mg/m2 and leukopenia was the dose-limiting toxicity. In the patients treated with G-CSF the MTD was 90 mg/m2, myelotoxicity being the dose-limiting toxicity. We observed 1/3 partial response (PR) with epirubicin at the dose of 75 mg/m2 and 2/6 PR at 90 mg/m2. These results would indicate the usefulness of a phase II study with epirubicin at the dose of 90 mg/m2 in association with conventional dose of vinorelbine with the support of G-CSF in advanced NSCLC.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
29A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1729-31
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer.
pubmed:affiliation
Cattedra di Oncologia Medica, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli, Federico II, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Clinical Trial, Phase I